CD8A and breast carcinoma: Thus, in breast cancer [389], IL-2 plays an anti-tumor effect [390] due to increased recruitment of IL-2-releasing NK cells and the induction of anti-apoptotic function in CD8+ T cells [391], the main effector of the antitumor response [392].